MVT-602 is an oligopeptide kisspeptin-1 receptor agonist and an investigational drug candidate for the treatment of women undergoing assisted reproduction, such as in vitro fertilization (IVF).
More than 200 study participants have received treatment with MVT-602 in Phase 1 and Phase 2 clinical trials.
MVT-602 is not approved by the FDA
Clinical Trial Results
MVT-602 is not approved by the FDA.
In October 2018, we presented data from a Phase 1 trial of MVT-602 at the American Society of Reproductive Medicine (ASRM) Scientific Congress. Results of this trial showed that administration of MVT-602 in 24 healthy premenopausal women in the follicular phase produced a dose-related increase in LH and expected post-dose increases in FSH and estrogen. Adverse events were similar between placebo and the MVT-602 groups with no apparent dose-related effects.
Recent News and Presentations
24 May 2019
Myovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
14 May 2019
Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids
13 May 2019
Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, May 14th to Discuss Results from Phase 3 LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids